| Literature DB >> 25110914 |
Małgorzata Fabijańska1, Kazimierz Studzian, Leszek Szmigiero, Agnieszka J Rybarczyk-Pirek, Arno Pfitzner, Barbara Cebula-Obrzut, Piotr Smolewski, Elżbieta Zyner, Justyn Ochocki.
Abstract
This paper describes the synthesis of trans-bis-(3-aminoflavone)dichloridoplatinum(ii) (trans-Pt(3-af)2Cl2; TCAP) for use as a potential anticancer compound, and the evaluation of its structure by elemental and spectral analyses, and X-ray crystallography. The complex demonstrated a significant cytotoxic effect against human and murine cancer cell lines, as well as weaker toxicity towards healthy cells (human peripheral blood lymphocytes) in comparison with cisplatin. Various biochemical and morphological methods confirm that the proapoptotic activity of trans-Pt(3-af)2Cl2 is markedly higher than the reference cisplatin. Our results suggest that trans-Pt(3-af)2Cl2 may have a different antitumour specificity from that of cisplatin.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25110914 DOI: 10.1039/c4dt01501k
Source DB: PubMed Journal: Dalton Trans ISSN: 1477-9226 Impact factor: 4.390